Roth Capital Downgrades Peregrine Pharmaceuticals (PPHM) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/4/2026
- US stock futures advance as strong AI-linked earnings continue
- Caterpillar stock jumps on strong earnings and revenue beat
- Optical component stocks rally on proposed U.S. ban on Chinese tech
- BofA says this memory stock could double. Here are 5 reasons why
- Merck shares rise on big Q2 earnings beat, adjusted FY outlook
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
Peregrine Pharma (PPHM) Discountinues Phase III SUNRISE Trial of Bavituximab
February 25, 2016 4:11 PM ESTPeregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) announced that it is discontinuing the companys Phase III SUNRISE trial of bavituximab in patients with previously treated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). The decision to stop the trial was based on the recommendation of the study's Independent Data Monitoring Committee (IDMC) following a pre-specified interim analysis performed after 33% of targeted overall events (patient deaths) in the study were reached. Results of the analysis demonstrated that the bavituximab plus docetaxel group did not show a sufficient improvement in overall survival as compared to the... More
